Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Post by NoGambleNoFuturon Jan 22, 2021 9:04pm
336 Views
Post# 32366557

Potential home run?

Potential home run?Hey guys, I came across this stock pick from a friend. I did a lot of due diligence and even watched their Q3 earnings presentation. I see that covid-19 tests helped their cash situation in Q3 significantly and must have also in Q4. They're expecting to launch Aristotle in Q1 2021 so either February or March since January is almost done. I never invested in bio companies cause I think they're all full of garbage that just have promises, but I'm thinking twice with this one because they're going to launch a product that they've spent 20 years of R&D. I think I might add a significant position and risk a lot of money here. Any thoughts??
<< Previous
Bullboard Posts
Next >>